The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | What factors affect response to checkpoint inhibitors in lung cancer?
Although immune checkpoint inhibition has been proven to be a successful approach in lung cancer, not all patients benefit from this therapy. Here, Wolf-Hervé Fridman, MD, PhD, of Inserm, Paris, France, explains the reasons behind the heterogeneous responses to immune checkpoint inhibitors in lung cancer patients. This video was taken at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.
